C-XYOVZoe Biosciences
PAI-1, APJ, cardiometabolic disease
modulatingbiologic
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-XYOV
C-XYOVC-XYOVPAI-1, APJ, cardiometabolic disease
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Zoe Biosciences Overview, Address & Contact Login Get Started Zoe Biosciences Biotechnology Research • United States • 1-10 Employees View Top Employees At Zoe Biosciences Company overview Headquarters United States Website zoebiosciences.com NAICS 541714 Employees 1-10 Socials Key Contact at Zoe Biosciences Layton Smith Vice President, Drug Discovery Email View Details View All Employees About Revenue Employees Insights Funding Tech Stack Trending Companies FAQ About Zoe Biosciences Longevity therapeutics for the 21st century View contact profiles from Zoe Biosciences $ Zoe Biosciences re
Zoe Biosciences CEO, Founder, Key Executive Team, Board of Directors & Employees Technology Vendors Recent Research Newsletter Media Support Login Who We Serve Function Corporate Strategy Corporate Venture Capital Venture Capital IT Corporate Innovation How VCs Use CB Insights Go to the video gallery → Industries Consumer & Retail Tech Insurance Healthcare Industrials Financial Services Professional Services Professional Services Learn More → Success Stories How We Help Understand Tech Markets Anticipate Competitor Strategy Determine Tech Strategy Connect with Tech Vendors & Partne … le Status Scott Gies Icahn School of Medicine at Mount Sinai , Longevity Vision Fund , Flow Research Collective , OS Fund , and Geisel School of Medicine at Dartmouth Founder, Chief Executive Officer Current Name Scott Gies Work History Icahn School of Medicine at Mount Sinai , Longevity Vision Fund , Flow Research Collective , OS Fund , and Geisel School of Medicine at Dartmouth Title Founder, Chief Executive Officer Status Current Learn more by requesting a demo Loading...
Scott Gies - CEO & Cofounder at Zoe Biosciences | The Org Platform Enrich Pricing Log in Sign up Zoe Biosciences Scott Gies Unverified Scott Gies CEO & Cofounder Contact Scott Gies is the CEO and cofounder of Zoe Biosciences, where they currently lead innovative projects in biotechnology. Previously, Scott held roles such as Head of Business Development & Strategic Partnerships at Flow Research Collective and Advisor at Longevity Vision Fund. As a Laboratory Scientist at Dartmouth College, they explored neural correlates of consciousness through octopus cognition and led the “mir
Scott Gies CEO Home Home Science Science Team Team Contact Contact Menu View all View all Scott Gies CEO Scott is the CEO of Zoe Biosciences, a biotech developing therapeutics for cardiometabolic diseases. Before founding Zoe, he led Business Development & Strategic Partnerships at the Flow Research Collective and advised the Longevity Vision Fund on biotech investments. His research background spans epigenetics and genomics (Sharp Lab, Mount Sinai), octopus cognition (Tse Lab, Dartmouth), computational autism research, and marine conservation in Madagascar. Scott holds a B.A. in Neuroscie
Zoe Biosciences Home Home Science Science Team Team Contact Contact Menu C o n t a c t Contact Location Headquarters Los Angeles, CA Inquiries [email protected] Sitemap Home Home Science Science Team Team Contact Contact Social Linkedin Linkedin Zoe Biosciences ©2025 Zoe Biosciences Sitemap Home Home Science Science Team Team Contact Contact Social Linkedin Linkedin Zoe Biosciences ©2025 Zoe Biosciences Sitemap Home Home Science Science Team Team Contact Contact Social Linkedin Linkedin Zoe Biosciences ©2025 Zoe Biosciences
VDP-87 [Assessment] Zoe Biosciences - Passed Proposals - Governance Forum | VitaDAO = 40rem)" rel="stylesheet" data-target="desktop" /> = 40rem)" rel="stylesheet" data-target="discourse-ai_desktop" /> = 40rem)" rel="stylesheet" data-target="poll_desktop" /> = 40rem)" rel="stylesheet" data-target="desktop_theme" data-theme-id="3" data-theme-name="sam's simple theme"/> Governance Forum | VitaDAO VDP-87 [Assessment] Zoe Biosciences Proposals Passed Proposals Paolo February 27, 2023, 10:44pm 1 One liner : An early-stage therapeutic biotech with two programs each centered on targets that are we … e has raised pre-seed funding from two longevity venture capital, Longevitytech Fund and Healthspan Capital.5 In the current seed round, Zoe is seeking $1.5M. VitaDAO would fund 100 k€ with equity terms. Team Scott Gies , CEO and Founder: Scott is the CEO of Zoe Biosciences and a former Advisor to Sergey Young’s Longevity Vision Fund. Scott’s mission is to advance biology that helps alleviate suffering. To that end, he helped build the Flow Research Collective, a company stud … & Strategic Partnerships, and worked on the scientific diligence team at OS Fund, a deep tech-focused VC firm. Scott’s research experience spans epigenetics/genetics work studying tandem repeats (Sharp Lab at Mount Sinai), cognition research in octopuses (Tse Lab at Dartmouth), in silico autism research (In Silico Biosciences), and marine biology conservation work in Madagascar. He graduated from Dartmouth College with a degree in neuroscience. Douglas Vaughan , CSO and F … humans. Science advances, 3(11), eaao1617. Senior expert evaluation digest This proposal has been evaluated by two scientists, two biotech venture capitalists, and two business experts, please find below a digest of their evaluation: Qualitative evaluation PAI-1 is genetically validated in humans, and their CSO has done high quality research on it. APJ is validated in the sense BioAge is working on the same target. Both MOAs are applicable to both age-related disease and long … in on best indication. Quantitative evaluation : The reviewers have scored the proposal on different aspects including general conviction, on a scale of 1-5 (with 5 being the highest). Here are the average scores * Novelty: 3.5 Feasibility & Data: 3.7 Relevance: 4 Science Team: 4.5 Market Advantage: 2.7 IP Potential: 3.2 Conviction score: 3.
Zoe Biosciences - PAI-1 Antibody Therapeutics | VitaDAO WHY LONGEVITY RESEARCH VITA LABS VITA TOKEN PROJECTS BLOG STORE GET VITA LOADING EQUITY A VITADAO PROJECT Zoe Biosciences - PAI-1 Antibody Therapeutics ageing metabolic disorders EQUITY Funding $100,000 Initiated 31.03.2023 Douglas Vaughan, MD CSO and Founder Layton Smith, PhD Sr. Advisor Scott Gies CEO and Founder AT A GLANCE Stage : Early-stage therapeutic biotech PROJECT LINKS View governance proposal View on-chain vote Funding $100,000 Initiated 31.03.2023 Douglas Vaughan, MD CSO and Founder Layton Smith, PhD Sr. Advisor Scott Gies CE … A GLANCE Stage : Early-stage therapeutic biotech PROJECT LINKS View governance proposal View on-chain vote An early-stage therapeutic biotech with two programs - each centered on targets that are well-validated both for longevity and aging-related diseases. Background Zoe Biosciences is an early-stage preclinical biotech developing breakthrough therapeutics for age-related diseases and aging itself focusing on drug targets that are well-validated both for longevity and aging
Zoe Biosciences Home Home Science Science Team Team Contact Contact Menu Our Leadership A team of seasoned physicians, scientists, and entrepreneurs Scott Gies CEO Douglas Vaughan, MD CSO Layton Smith, PhD VP, Drug Discovery Paul Declerk, PhD, PHARMD Scientific Advisory Board Benjamin Singer, MD Scientific Advisory Board Vibeke Strand, MD Scientific Advisory Board Karl Scheidt, PhD Scientific Advisory Board Gary Schiltz, PhD Scientific Advisory Board Josh Cheema, MD, MSCI, MSAI Scientific Advisory Board Contact Us Contact Us Sitemap Home Home Science Science Team Team Contact Contact Social Li
Douglas Vaughan, MD CSO Home Home Science Science Team Team Contact Contact Menu View all View all Douglas Vaughan, MD CSO Dr. Vaughan is the Irving S. Cutter Professor of Medicine at Northwestern University and the Founding Director of the Potocsnak Longevity Institute, a multidisciplinary institute looking to expand human healthspan. He is the former Chairman of the Department of Medicine at Northwestern University Feinberg School of Medicine, the former Physician in Chief of Northwestern Memorial Hospital, and the former Chief of Cardiology at Vanderbilt University. His lab has been at the
Zoe Biosciences achieves milestone with G-protein biased APJ agonist | Layton Smith posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign
Zoe Biosciences Home Home Science Science Team Team Contact Contact Menu R e d e f i n i n g c a r d i o m e t a b o l i c a g i n g . R e d e f i n i n g c a r d i o m e t a b o l i c a g i n g . Contact Zoe Biosciences is developing best-in-class therapies to treat cardiometabolic disease. Zoe Biosciences is developing best-in-class therapies to treat cardiometabolic disease. Introduction We have leveraged decades of combined research to build therapies targeting PAI-1 and APJ. Learn More Lead Indications OVERVIEW Heart failure (HFpEF) Learn More 1. Heart failure (HFpEF) OVERVIEW Heart failu
Zoe Biosciences Home Home Science Science Team Team Contact Contact Menu M e d i c i n e f o r t h e 2 1 s t c e n t u r y Our Story In 2015, Zoe’s CSO, Dr. Douglas Vaughan, and collaborators identified a naturally occurring mutation in an Amish community that lowers PAI-1—the primary inhibitor of fibrinolysis and a key regulator of cellular senescence. Carriers live about ten years longer on average and exhibit lower rates of chronic disease than non-carriers. Guided by these human genetic insights, Zoe Biosciences is developing therapies targeting cardiometabolic aging across two drug progra